Radnostix Inc. Reports 27% Revenue Decline and Increased Net Loss in Q1 2026

Radnostix Inc. reported a significant decline in financial performance for the first quarter of 2026, with total revenue of $2.38 million, down approximately 27% from $3.24 million in the same period of 2025. The decrease was primarily attributed to lost sales in the Theranostics Products segment due to voluntary recalls of its Generic Sodium Iodide I-131 and Dibasic Sodium Phosphate Capsules, as well as reduced sales in the Cobalt Products segment due to operational shutdowns for maintenance. The company also experienced a net loss of $1.35 million for the quarter, compared to a loss of $112,694 in the prior year, reflecting a substantial increase in operating expenses and the impact of the recalls.

Operating costs rose by 17% to $2.46 million, driven by increased salaries, general administrative expenses, and research and development costs. Notably, stock-based compensation expenses included an out-of-period adjustment of $102,441, contributing to the overall increase in operating expenses. The gross profit for the quarter was $1.15 million, down 43% from $2.03 million in the previous year, primarily due to lower sales and higher costs associated with the recalls.

In terms of operational developments, Radnostix has been focusing on its core business segments, particularly Theranostics Products, Cobalt Products, and Calibration & Reference Products. The company is also in the process of developing its Medical Device segment, which includes products acquired from AMICI, Inc. The Medical Device segment reported a 69% increase in sales to $89,113, indicating growth potential despite the overall decline in revenue. The company is targeting a rollout of its EasyFill Automated Iodine Capsule System by Q3 2026.

Radnostix's balance sheet showed total assets of $17.19 million as of March 31, 2026, a decrease from $17.84 million at the end of 2025. Current liabilities increased to $4.45 million, up from $3.97 million, largely due to higher accounts payable and accrued liabilities. The company’s cash and cash equivalents decreased to $1.35 million, down 21% from the previous quarter, reflecting the impact of operational losses and investments in property and equipment.

Looking ahead, Radnostix expects that cash from operations, along with potential equity or debt financing, will be sufficient to fund its operations for the next twelve months. The company is evaluating options for its Fluorine Products segment and the DUF6 de-conversion facility, which may include joint ventures or divestitures. The management remains optimistic about the long-term growth prospects in the radioisotope and radiopharmaceutical markets, particularly in light of the anticipated recovery from the recent product recalls and ongoing development efforts in its Medical Device segment.